An interventional study of Videodensitometric guided and Stand of care guided in Aortic Stenosis, sponsored by Xijing Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Diagnostic
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 7th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 37 with no phase, reaches primary completion later than 28 of the 50 other live ones, and was the 51st registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Yan'an Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18+
Beijing Balance Medical Technology Co., Ltd · Sites in China
Ages 60–100
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 120 across the 47 interventional studies, 490 across the 22 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial, a prospective, randomized, multicenter study, assigns patients to either videodensitometry-guided TAVI or conventional TTE/TEE-guided TAVI (stand of care), with the primary endpoint being regurgitation fraction measured by cardiac magnetic resonance (CMR) at discharge. Current AR assessment methods, like subjective visual grading or intraprocedural TTE, face limitations in objectivity and practicality, whereas videodensitometry offers real-time, quantitative feedback to guide corrective actions (e.g., post-dilation) during TAVI. If proven non-inferior, this approach could streamline workflows by reducing reliance on general anesthesia and complex imaging, potentially lowering complications and expanding accessibility, particularly in centers lacking advanced echocardiography resources.
As the transcatheter aortic valve implantation (TAVI) procedure matures, complications such as paravalvular regurgitation (PVR), stroke, conduction disturbances, vascular complications, and annular rupture have been targeted for further improving the long-term outcome of TAVI. Paravalvular regurgitation (PVR) is associated with mortality following TAVI, even in those with mild PVR. Accurate procedural assessment of AR-critical for successful TAVI. Aortic root angiography, typically using Seller's visual grading, is the first screening tool used in most laboratories for the detection of post-implantation AR and guidance of timely corrective measures (e.g. post-dilation, valve-in-valve and, most recently, retrieval and reposition of the valve). However, the Sellers classification of aortic regurgitation (AR) is subjective. Some centers use transthoracic echo to confirm residual AR. However, performing transthoracic echo in the Cath-lab in a prone position is challenging. Previous studies have demonstrated that TAVI performed exclusively under angiographic guidance with backup TTE is feasible and associated with reasonably good outcomes, similar to those of angiography and TEE-guided procedures. Quantitative aortographic assessment of AR is important for procedural TAVI guidance to facilitate timely decision-making to avert AR using balloon post-dilatation, retrieval-reposition, or valve-in-valve implantation.
CAAS A-Valve (quantitative assessment of regurgitation with videodensitometry in the left ventricle outflow tract) is a new tool to quantify AR developed by Pie Medical. This tool is an angiographic methodology that proved to be accurate, feasible, reproducible, and predictive of outcomes after TAVI. After extensive validation of this new technology in two different cohorts (from the Brazilian TAVI registry and Bad-Segeberg, Germany), hereby we propose to apply this currently off-line technology to guide decision making in the Cath-lab during TAVI.
The present trial is a prospective, randomized, controlled, open-label, multi-center, non-inferiority trial. The primary objective of this trial is to determine whether TAVI procedure guided by videodensitometric assessment of aortography is non-inferior to TAVI implantation guided by Standard of care (usual practice) in terms of postprocedural quantitative aortic regurgitation. The primary endpoint of the study will be the Cardiac magnetic resonance-derived regurgitation fraction at discharge. This project is the first study to investigate the clinical utility of using video-densitometry in a randomized, controlled clinical trial to guide TAVI procedure. In centers with no current CAAS-A Valve software, Pie Medical will provide a research lease during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAVI procedure guided by post-implantation aortographic quantitative videodensitometric assessment.
Diagnostic Test: Videodensitometric guided
TAVI procedure guided by post-implantation standard of care according to local practice.
Diagnostic Test: Stand of care guided
In the experimental arm, a TAVI device is implanted according to the local practice. Immediately after implantation, aortography is performed to quantitatively assess the aortic regurgitation (qAR). The aortography is analyzed using CAAS A-Valve (Pie-Medical, Maastricht, The Netherlands). •If qAR is \>17%, we recommend that corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed and angiography is repeated for the assessment of aortic regurgitation. If the qAR ≤17%, whether corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed is left to the discretion of the operators. Inform operators of the results of qAR and the threshold criteria. Continuous qAR was stratified into categorical variables according to the following pre-determined threshold criteria: (1) none or trace (qAR \<6%); (2) mild (6% to ≤17%); and (3) moderate or severe (\>17%). At discharge, all the patients will undergo Cardiac magnetic resonance, the Car
In the control arm, a TAVI device is implanted according to local practice. Immediately after implantation, TEE/TTE or aortography is performed as a part of usual practice. * The requirement of post-dilatation or any additional procedure is left to the discretion of the operator. * The operator judges the sufficient procedural outcome to end the procedure according to local practice. At discharge, all the patients will undergo Cardiac magnetic resonance, the Cardiac magnetic resonance-derived regurgitation fraction (CMR-RF) will be analyzed as the primary endpoint.
CMR-derived regurgitation fraction
The Cardiac magnetic resonance-derived regurgitation fraction at discharge.
Time frame: at discharge 1 day, an average of 7days
Medical cost
Direct medical cost at discharge
Time frame: at discharge 1 day, an average of 7days
Radiation dose
Amount of radiation dose
Time frame: during the procedure
Time in the Cathlab
Time in the Cathlab
Time frame: during the procedure
Time for the TAVI procedure
Time for the TAVI procedure
Time frame: during the procedure
All-cause mortality and its sub-categories
All-cause mortality and its sub-categories defined by VARC 3
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
All strokes
All strokes
Time frame: at discharge 1 day, an average of 7days;30-day; 1 year
Any hospitalization and its sub-categories
Any hospitalization and its sub-categories defined by VARC 3
Time frame: 30-day, 1 year
Acute Kidney Injury (AKI)
Acute Kidney Injury (AKI)(VARC 3 criteria: use the widely recognized kidney disease: Improving Global Outcomes (KDIGO) definition of AKI)
Time frame: at discharge 1 day, an average of 7days; 30-day
Type 3 (life-threatening) or Type 4 (leading to death) bleeding
Type 3 (life-threatening) or Type 4 (leading to death) bleeding (VARC-3 criteria)
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
Mild or more prosthetic valve regurgitation
Mild or more prosthetic valve regurgitation \[TTE assessment
Time frame: 30-day, 1 year
New permanent pacemaker implantation
New permanent pacemaker implantation \[VARC-3 criteria\]
Time frame: at discharge 1 day, an average of 7days; 30-day, 1 year
Conduction disturbances and arrhythmias
Conduction disturbances and arrhythmias according to VARC-3
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
Technical success:
* Freedom from mortality * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of a single prosthetic heart valve into the proper anatomical location * Freedom from surgery or intervention related to the devicea or to a major vascular or access-related, or cardiac structural complication
Time frame: patient exit from procedure room,whichever came first,assessed up to 30 minutes
Device success
* Technical success * Freedom from mortality * Freedom from surgery or intervention related to the devicea or to a major vascular or access-related or cardiac structural complication * Intended performance of the valvec (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index \>_0.25, and less than moderate aortic regurgitation)
Time frame: 30-day
Myocardial infarction
Myocardial infarction (VARC-3 criteria)
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
Vascular and access-related complications
Vascular and access-related complications (VARC-3 criteria)
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
Cardiac structural complications
Cardiac structural complications (VARC-3 criteria)
Time frame: at discharge 1 day, an average of 7days; 30-day; 1 year
Any adverse events
Any adverse events
Time frame: within 7 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 33 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.